Conditions: Metastatic Progressive Castration-resistant Prostate Cancer
Allocation:  | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.

Detailed description:

Arms:
arm 1: Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.

Interventions: intervention 1: Enzalutamide
Intervention descriptions: intervention 1: None

Protocol document: